Novo Nordisk Rises After Bowing Out of Metsera Takeover Battle
Novo Nordisk A/S shares rose after the Danish drugmaker withdrew from a $10 billion takeover battle for obesity drug developer Metsera Inc., clearing the way for Pfizer Inc.
By Frank Connelly · Bloomberg Markets
Novo Nordisk A/S shares rose after the Danish drugmaker withdrew from a $10 billion takeover battle for obesity drug developer Metsera Inc., clearing the way for Pfizer Inc.